Alle Filter zurücksetzen
Kategorien
  • Pharma / Gesundheit
  • Pharmaindustrie / Medikamente
  • Schmerzen / Migräne / Analgetika
  • Filter zurücksetzen
Regionen/Länder
  • Europa
  • Belgien
  • Bosnien-Herzegowina
  • Bulgarien
  • Dänemark
  • Deutschland
  • Estland
  • Finnland
  • Frankreich
  • Griechenland
  • Irland
  • Italien
  • Kroatien
  • Lettland
  • Litauen
  • Mazedonien
  • Niederlande
  • Norwegen
  • Österreich
  • Poland
  • Portugal
  • Rumänien
  • Russian Federation
  • Schweden
  • Schweiz
  • Serbien
  • Slowakei
  • Slowenien
  • Spanien
  • Tschechien
  • Türkei
  • Ukraine
  • Ungarn
  • Vereinigtes Königreich
  • Weißrussland
  • Weißrussland
  • Asien / Pazifik
  • China
  • Hong Kong
  • Indien
  • Indonesien
  • Japan
  • Kasachstan
  • Malaysia
  • Neuseeland
  • Pakistan
  • Philippinen
  • Singapur
  • Südkorea
  • Taiwan
  • Thailand
  • Usbekistan
  • Vietnam
  • Mittlerer Osten / Afrika
  • Ägypten
  • Algerien
  • Iran
  • Israel
  • Kamerun
  • Kenia
  • Marokko
  • Nigeria
  • Saudi Arabien
  • South Africa
  • Tunesien
  • Vereinigte Arabische Emirate
  • Nordamerika / USA
  • Kanada
  • United States
  • Australien
  • Mittel- / Südamerika
  • Argentinien
  • Bolivien
  • Brasilien
  • Chile
  • Costa Rica
  • Kolumbien
  • Mexiko
  • Peru
  • Uruguay
  • Venezuela
  • Filter zurücksetzen
Herausgeber
  • Biopharm Reports
  • Canadean
  • Datamonitor
  • Euromonitor
  • GBI Research
  • Global Markets Direct
  • GlobalData
  • Life Science Analytics
  • Technavio
  • Filter zurücksetzen
Sprache
  • Englisch
  • Filter zurücksetzen
Datum
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • Filter zurücksetzen
laedt

Marktanalyse - Analgesics in Belgium

Euromonitor

Euromonitor

6 / 2012
35 Seiten
Typ: Marktanalyse
Sprache: Englisch
Regionen: Belgien
Verfügbarkeit: verfügbar

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

675,00 €*
PDF-Datei per E-Mail , versandkostenfrei


Industry consensus was that the end of 2010 and 2011 were atypically dynamic in terms of innovation. Novelties were interesting, including notably Dafalgan Agrume Effervescent, smaller variants of Dafalgan. It enabled manufacturers to offset a rather disappointing year in terms of infectious diseases. After the very cold autumn of 2010 enabled that year to end better than initially expected, the number and strength of infectious diseases was low in 2011: the winter was mild, the spring was warm...

Euromonitor International's Analgesics in Belgium report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2007-2011, allowing you to identify the sectors driving growth. Forecasts to 2016 illustrate how the market is set to change.

Product coverage: Systemic Analgesics, Topical Analgesics/Anaesthetic.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Analgesics market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
ANALGESICS IN BELGIUM

Euromonitor International

June 2012



LIST OF CONTENTS AND TABLES



Headlines

Trends

Switches

Competitive Landscape

Prospects

Category Data

Table 1 Sales of Analgesics by Category: Value 2006-2011

Table 2 Sales of Analgesics by Category: % Value Growth 2006-2011

Table 3 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2006-2011

Table 4 Analgesics Company Shares by Value 2007-2011

Table 5 Analgesics Brand Shares by Value 2008-2011

Table 6 Forecast Sales of Analgesics by Category: Value 2011-2016

Table 7 Forecast Sales of Analgesics by Category: % Value Growth 2011-2016

Executive Summary

Slight But Fragile Recovery in 2011

Negative Environment for Consumer Health Affects Sales

Disparate Results in A Still Fragmented Competitive Environment

Distribution Remains Under the Control of Pharmacies Despite Some Changes

Bleak Prospects Overall

Key Trends and Developments

Fragile Economic Recovery To Result in A Temporary Improvement

Authorities and Medical Experts Blow Hot and Cold

More Health & Wellness, Certainly, But Also More Realism

Remedies for Increasingly Stressful Lifestyles

Brand Equity To Remain the Key in A Restricted Environment

Market Indicators

Table 8 Consumer Expenditure on Health Goods and Medical Services 2006-2011

Table 9 Life Expectancy at Birth 2006-2011

Market Data

Table 10 Sales of Consumer Health by Category: Value 2006-2011

Table 11 Sales of Consumer Health by Category: % Value Growth 2006-2011

Table 12 Consumer Health Company Shares 2007-2011

Table 13 Consumer Health Brand Shares 2008-2011

Table 14 Penetration of Private Label by Category 2006-2011

Table 15 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011

Table 16 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011

Table 17 Forecast Sales of Consumer Health by Category: Value 2011-2016

Table 18 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016

Appendix

OTC Registration and Classification

Vitamins and Dietary Supplements - Registration and Classification

Switch Climate

Self-medication and Preventative Medicine

Generics

Switches

Summary 1 OTC - Switches 2009-2011

Sources

Summary 2 Research Sources

*Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

Für Sie protokollierte Studien / Marktanalysen:
  zuletzt angesehene Studien: